Lupin expects 25-30 product approvals in FY 2016

20 Apr 2015 Evaluate

Lupin is expecting 25-30 product approvals in FY 2016 and the number for financial year 2017 is likely to be even higher than this. With 10 final approvals in the past 12 months, the company has led the Indian pharma peers on this metric.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally.

Lupin Share Price

2150.25 18.45 (0.87%)
30-Jan-2026 15:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1598.00
Dr. Reddys Lab 1215.70
Cipla 1328.40
Zydus Lifesciences 888.50
Lupin 2150.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×